# JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation

> **NCT04429191** · PHASE1 · UNKNOWN · sponsor: **Jasper Therapeutics, Inc.** · enrollment: 40 (estimated)

## Conditions studied

- MYELODYSPLASTIC SYNDROME; MDS
- ACUTE MYELOID LEUKEMIA; AML

## Interventions

- **BIOLOGICAL:** Humanized anti-CD117 Monoclonal Antibody (JSP191)

## Key facts

- **NCT ID:** NCT04429191
- **Lead sponsor:** Jasper Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-08
- **Primary completion:** 2023-10-15
- **Final completion:** 2023-12-08
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2021-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04429191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04429191, "JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04429191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*